🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

493 results for “Regeneron UK Limited” Clear

  1. Fasinumab

    Regeneron UK Limited

    Low Back Pain

    phase 3 small molecule completed

    1 trial

  2. Fasinumab

    Regeneron UK Limited

    Chronic Low Back Pain

    phase 3 small molecule terminated

    1 trial

  3. Fianlimab

    Regeneron UK Limited

    Melanoma

    phase 3 small molecule active

    3 trials

  4. Garetosmab

    Regeneron UK Limited

    Fibrodysplasia Ossificans Progressiva

    phase 3 small molecule active

    1 trial

  5. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  6. Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  7. Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)

    Regeneron UK Limited

    Branch Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  8. Intravitreal aflibercept injection [IAI]

    Regeneron UK Limited

    Nonproliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  9. Itepekimab (SAR440340)

    Regeneron UK Limited

    Chronic Rhinosinusitis With Nasal Polyps

    phase 3 small molecule active

    4 trials

  10. Itepekimab SAR440340

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    4 trials

  11. LMT (atorvastatin, simvastatin, or rosuvastatin)

    Regeneron UK Limited

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  12. Linvoseltamab

    Regeneron UK Limited

    Multiple Myeloma (MM)

    phase 3 small molecule active

    1 trial

  13. Linvoseltamab

    Regeneron UK Limited

    High Risk Smoldering Multiple Myeloma (HR-SMM)

    phase 3 small molecule active

    1 trial

  14. Linvoseltamab

    Regeneron UK Limited

    Relapsed and/or Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    1 trial

  15. Linvoseltamab

    Regeneron UK Limited

    Multiple Myeloma

    phase 3 small molecule active

    6 trials

  16. Linvoseltamab

    Regeneron UK Limited

    Relapsed Refractory Multiple Myeloma (RRMM)

    phase 3 small molecule active

    2 trials

  17. Mibavademab

    Regeneron UK Limited

    Generalized Lipodystrophy

    phase 3 small molecule active

    2 trials

  18. Mibavademab

    Regeneron UK Limited

    Monogenic Obesity

    phase 3 small molecule active

    1 trial

  19. NTLA-2001

    Regeneron UK Limited

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 mab active

    1 trial

  20. Odronextamab

    Regeneron UK Limited

    Diffuse Large B-cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  21. Odronextamab

    Regeneron UK Limited

    Follicular Lymphoma (FL)

    phase 3 small molecule active

    2 trials

  22. Odronextamab

    Regeneron UK Limited

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  23. Odronextamab

    Regeneron UK Limited

    B-Cell Non-Hodgkin Lymphoma (B-NHL)

    phase 3 small molecule active

    2 trials

  24. Pemetrexed

    Regeneron UK Limited

    Carcinoma，Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources